News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Announces LOXL2 Inhibitor Program is Phase 2 Ready Following Completion of 13 Week Toxicity Studies
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that it has now received reports on all of the 13-week toxicity studies conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors. Together with the previously released results of Pharmaxis phase 1 clinical trials for both compounds showing best in class target engagement from a once a day oral dose, Pharmaxis believes that this program is now ready to enter phase 2 clinical studies for fibrotic diseases such as NonâAlcoholic Steatohepatitis (NASH), cardiac fibrosis and Idiopathic Pulmonary Fibrosis (IPF).
Read full media release - pdf